Neoadjuvant Chemotherapy vs. Cytoreductive Surgery

Neoadjuvant chemotherapy (NACT) followed by interval cytoreductive surgery (ICS) has become the leading initial treatment for advanced epithelial ovarian cancer (EOC). This approach offers advantages in managing this complex disease. It also represents a significant shift in treatment strategies, as highlighted by numerous studies and articles.

By 2021, the combination of NACT and ICS had established itself as the standard initial treatment for advanced EOC, effectively replacing primary cytoreductive surgery (PCS) as the first line of intervention, and despite PCS being recommended through national guidelines continuously.

Treatment Outcomes and Survival

Adding bevacizumab to the neoadjuvant chemotherapy regimen of carboplatin and paclitaxel has been shown to significantly improve progression-free survival (PFS), although its impact on overall survival (OS) in patients with EOC remains limited. This finding comes from a study analyzing the efficacy and safety of incorporating bevacizumab into the treatment plan.

Addressing Patient and Caregiver Needs

The recurrence of epithelial ovarian cancer markedly elevates the psychological, physical, and informational needs of both patients and their caregivers. Supportive care interventions are essential in addressing these unmet needs.

Treatment Patterns and Patient Involvement

Patient involvement in first-line treatment decisions continues to be limited in both Europe and the US. Treatment selection is largely driven by national and international guidelines rather than patient preferences.

In conclusion, the focus on NACT with ICS marks a pivotal shift in treating advanced epithelial ovarian cancer. Additional therapies like bevacizumab and PARP inhibitors are becoming increasingly important in enhancing progression-free survival. However, to better address patients and caregivers needs, greater patient involvement in treatment decisions and comprehensive supportive care remain critical.